绿康生化股份有限公司 第五届董事会独立董事专门会议 第八次会议决议 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）第五届董事会 第八次独立董事专门会议于 2025 年 4 月 27 日以通讯的方式召开。本次会议应 到独立董事 3 名，实到独立董事 3 名；会议由独立董事狄旸女士主持，符合《公 司法》《公司章程》《上市公司独立董事管理办法》和《公司独立董事工作制度》 的有关规定。 2025 年 4 月 27 日 1 1、审议通过了《关于公司向关联方支付利息暨关联交易的议案》 本次交易符合公司开展员工持股计划以不断吸引和留住优秀人才的需要，根 据市场情况及关联方实际付出的融资成本，本次关联交易定价公允、合理。交易 遵循了客观、公平、公允的原则，符合公司的根本利益，不会损害公司及全体股 东特别是中小股东的合法权益。审议表决本次交易事项的程序合法有效，符合《中 华人民共和国公司法》《中华人民共和国证券法》等有关法律法规和《公司章程》 的规定，我们一致同意将本议案提交董事会审议。 绿康生化股份有限公司 独立董事专门会议 经与会委员认真审议，本次会议各位委员审议并通过了以下议案： ...

证券代码：002868 证券简称：绿康生化 公告编号：2025-044 绿康生化股份有限公司 三、2024 年度不进行利润分配的的合法性、合规性及合理性 2024 年度不进行利润分配是在保证公司正常经营和长远发展的前提下，综合 考虑公司的经营发展及广大投资者的利益等因素提出的，符合根据《关于进一步落 实上市公司现金分红有关事项的通知》《上市公司监管指引第 3 号——上市公司现 金分红》《上市公司自律监管指引第 1 号——主板上市公司规范运作》《公司章 程》等相关规定，符合公司确定的利润分配政策、利润分配计划以及做出的相关承 诺，符合公司未来经营发展的需要，具备合法性、合规性及合理性。 四、备查文件 关于公司 2024 年度拟不进行利润分配的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）于 2025 年 4 月 27 日召开的第五届董事会第十六次会议和第五届监事会第十二次会议审议通过了 《关于公司 2024 年度拟不进行利润分配的议案》，本议案尚需提交公司 2024 年 度股东会审议批准。 一、利润分 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 绿康生化股份有限公司 关于公司股票被实施退市风险警示及 其他风险警示暨停牌的公告 证券代码：002868 证券简称：绿康生化 公告编号：2025-051 1、绿康生化股份有限公司（以下简称"公司"）股票将于 2025 年 4 月 29 日（星期二）开市起停牌一天，并于 2025 年 4 月 30 日（星期三）开市起复牌。 2、股票简称：由"绿康生化"变更为"*ST 绿康"； 3、股票代码：无变化，仍为"002868"； 4、实施退市、其他风险警示的起始日：公司股票将于 2024 年度报告披露日 （2024 年 4 月 29 日）停牌一天，自 2025 年 4 月 30 日复牌之日起，深圳证券交 易所对公司股票交易实施退市、其他风险警示； 5、实行退市、其他风险警示后股票交易的日涨跌幅限制为 5%。 二、公司股票交易被实施退市风险警示的原因 公司 2024 年经审计期末净资产为-24,536,065.37 元，触及《深圳证券交易所 股票上市规则》第 9.3.1 条(二)"最近一个会计年度经审计的期末净资 ...

Financial Performance - The net loss for 2024 was CNY 444.86 million, with a net loss of CNY 464.47 million after deducting non-recurring gains and losses[7]. - The company has experienced negative net profits for three consecutive years, with 2022 and 2023 losses of CNY 121.94 million and CNY 221.82 million, respectively[7]. - The net profit attributable to shareholders for 2024 was -¥444,864,018.29, a decline of 100.55% from -¥221,817,878.58 in 2023[27]. - The company's operating revenue for 2024 reached ¥649,373,107.41, representing a 28.08% increase compared to ¥507,004,856.86 in 2023[27]. - The basic earnings per share for 2024 was -¥2.86, compared to -¥1.44 in 2023, reflecting a 98.61% decline[28]. - The company reported a total loss of ¥428,149,962.79, primarily due to low gross margins in the photovoltaic film sector and significant fixed asset impairments[56]. Assets and Liabilities - As of December 31, 2024, the company's total current liabilities exceeded current assets by CNY 1.03 billion, and the net assets were negative CNY 24.54 million[4]. - The total assets at the end of 2024 were ¥1,491,670,606.60, down 24.09% from ¥1,965,009,357.76 at the end of 2023[28]. - The company's net assets attributable to shareholders turned negative at -¥26,267,391.62 by the end of 2024, a decrease of 106.39% from ¥411,287,522.61 in 2023[28]. - The company reported a net asset of -24,536,065.37 RMB at the end of 2024, triggering a delisting risk warning as per the Shenzhen Stock Exchange regulations[105]. Operational Challenges - The company plans to implement a risk warning for its stock due to negative net assets and continuous operating uncertainties[6]. - The company has highlighted significant risks in its future operations, which investors should be aware of[4]. - The company is currently in negotiations regarding a potential change in control, which carries significant uncertainty[7]. - The company has reported uncertainty regarding its ability to continue as a going concern due to negative net profits over the last three years[28]. Revenue Streams - The revenue after deducting certain income was ¥610,679,900.22 for 2024, compared to ¥489,932,458.50 in 2023[27]. - The revenue from the photovoltaic film business reached ¥231,301,932.52, representing a 60.89% increase year-over-year[61]. - The veterinary medicine segment reported revenue of 351,490,551, an increase of 7.35% year-over-year[63]. - Domestic sales accounted for ¥455,926,086.87, up 31.36% from the previous year, while international sales increased by 20.97% to ¥193,447,020.54[61]. Research and Development - Research and development expenses increased by 29.16% to 35,557,483.16, reflecting higher investment in photovoltaic film development[72]. - The company has several ongoing R&D projects aimed at optimizing production processes and enhancing product competitiveness, including RD39 and RD37 for Avilamycin and Monensin production[73]. - The company is currently developing new products like thermoplastic POE film and HJT light conversion film to enhance product variety and market competitiveness[74]. - The company has not capitalized any R&D investments in both 2023 and 2024, maintaining a 0.00% capitalization rate[74]. Environmental Compliance - The company has received approval for various environmental impact reports, including a project for producing 1200 tons of active microbial additives annually, which was approved in September 2022[176]. - The company’s wastewater treatment project at the Putan plant completed its environmental protection acceptance in April 2023, indicating compliance with environmental standards[176]. - The company has successfully renewed its pollution discharge permits in September 2023, ensuring continued compliance with environmental laws[177]. - The company has established emergency response plans for environmental incidents, with the latest revisions completed in March 2023[181]. Governance and Management - The company has established a complete independent business system and operational capabilities, ensuring independence from its controlling shareholder[115]. - The governance structure of the company is in line with the requirements set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[114]. - The company has maintained a consistent board of directors and supervisory board with no significant changes in personnel[120]. - The company has a strict remuneration decision-making process based on its articles of association and performance evaluations[133]. Market Strategy - The company is actively pursuing market expansion strategies, including potential mergers and acquisitions, as part of its growth initiatives[118]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[124]. - The company is committed to establishing stable supply chain partnerships with major domestic livestock groups to mitigate procurement risks[98]. - The company is focusing on enhancing the quality and reliability of its existing products to strengthen market competitiveness[97].

Financial Performance - The company's revenue for Q1 2025 was ¥141,922,869.97, a decrease of 11.52% compared to ¥160,395,845.10 in the same period last year[5] - The net loss attributable to shareholders was ¥29,408,859.45, showing an improvement of 6.17% from a loss of ¥31,342,797.54 in the previous year[5] - The company's basic and diluted earnings per share improved to -¥0.19, a 5.00% increase from -¥0.20 in the same period last year[5] - The company reported a net loss of ¥29,313,726.17 for the current period, an improvement from a net loss of ¥31,573,220.52 in the previous period, representing a decrease in loss of approximately 7.2%[22] - Operating profit was recorded at -¥30,374,532.03, compared to -¥39,561,575.59 in the previous period, indicating a significant reduction in operating losses by about 23.5%[22] - The company’s total comprehensive income for the period was -¥29,313,726.17, compared to -¥31,573,220.52 in the previous period, showing a reduction in comprehensive losses of approximately 7.2%[22] Cash Flow and Assets - The net cash flow from operating activities increased significantly to ¥32,909,805.04, a 315.89% improvement from -¥15,243,576.62 in the same period last year[5] - Cash flow from operating activities generated a net inflow of ¥32,909,805.04, a turnaround from a net outflow of -¥15,243,576.62 in the previous period[23] - Total cash and cash equivalents at the end of the period stood at ¥12,330,079.08, down from ¥68,380,217.19 at the end of the previous period, reflecting a decrease of approximately 82%[24] - The company’s cash and cash equivalents decreased significantly to CNY 12,330,079.08 from CNY 24,799,981.20, a decline of 50.3%[19] - The company’s investment activities resulted in a net cash outflow of -¥18,214,802.02, an improvement from -¥55,089,070.36 in the previous period[23] Liabilities and Equity - Total assets at the end of the reporting period were ¥1,444,745,643.94, down 3.15% from ¥1,491,670,606.60 at the end of the previous year[5] - The company’s total liabilities decreased by 125.95%, with shareholders' equity at -¥55,439,382.62 compared to -¥24,536,065.37 at the end of the previous year[5] - Total liabilities decreased to CNY 1,498,358,567.03 from CNY 1,516,206,671.97, a reduction of 1.2%[19] - The company reported a financial expense of CNY 12,263,056.41, which is a decrease of 24.6% from CNY 16,270,060.42 in the previous period[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,037, with the largest shareholder holding 30.43% of the shares[12] - A share transfer agreement has been signed to transfer 46,608,397 shares, representing 29.99% of the total share capital, from existing shareholders to Fujian Zongteng Network Co., Ltd.[15] - The control of the company will change from Shanghai Kangyi Investment Co., Ltd. to Fujian Zongteng Network Co., Ltd. after the share transfer is completed[15] - The major shareholders involved in the share transfer do not have any known relationships or agreements among themselves[15] Business Operations and Future Outlook - The company plans to sell assets related to its photovoltaic film business, with the transaction price yet to be determined pending asset evaluation[16] - The asset transfer agreement requires approval from the board and shareholders before implementation, indicating uncertainty in the transaction[16] - The company has experienced significant uncertainty regarding its ability to continue as a going concern, as highlighted in recent audit reports[15] - The company is currently in discussions regarding the control change, which carries significant investment risks for stakeholders[15] Research and Development - Research and development expenses were CNY 7,603,451.73, slightly down from CNY 7,835,076.19, reflecting a decrease of 3.0%[21] Inventory and Operating Costs - Total operating costs amounted to CNY 167,385,044.46, down 11.2% from CNY 188,466,936.22 in the prior period[21] - Inventory increased to CNY 105,878,765.92, up 10.6% from CNY 95,713,633.87[19] - The company reported a significant increase in investment income of ¥892,827.25, compared to a loss of -¥62,958.88 in the previous year, marking a change of -1518.11%[9] - Cash received from government subsidies related to operating activities decreased by 93.81% to ¥1,158,140.81 from ¥18,700,481.99 in the previous year[10]

绿康生化股份有限公司 详式权益变动报告书 上市公司名称：绿康生化股份有限公司 股票上市地点：深圳证券交易所 股票简称：绿康生化 股票代码：002868.SZ 信息披露义务人：福建纵腾网络有限公司 注册地址：福建省福州市仓山区建新镇杨周路 23 号 3 号楼 4 层 302-1、303-1 通讯地址：深圳市龙岗区坂田街道坂雪岗大道与永香路交叉口创汇国际中心 15 层 权益变动性质：股份增加（协议转让） 签署日期：2025 年 4 月 绿康生化股份有限公司 详式权益变动报告书 信息披露义务人声明 一、本报告书系根据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》、《公开发行证券的公司信息披露内容与格式准则 第 16 号——上市公司收购报告书》及相关的法律、法规和部门规章的有关规定 编制。 三、截至本报告书签署日，信息披露义务人签署本报告书已获得必要的授权 和批准，其行为亦不违反信息披露义务人公司章程或内部规则中的任何条款，或 与之相冲突。 四、本次权益变动是根据本报告书所载明的资料进行的。除信息披露义务人 和 ...

信息披露义务人：上饶市长鑫贰号企业管理中心（有限合伙） 住所：江西省上饶经济技术开发区金融产业园 A 区 5 号楼 7 楼 通讯地址：江西省上饶经济技术开发区金融产业园 A 区 5 号楼 7 楼 股份权益变动性质：股份减少（协议转让） 签署日期：二〇二五年四月二十七日 1 上市公司：绿康生化股份有限公司 上市地点：深圳证券交易所 股票简称：绿康生化 股票代码：002868.SZ 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号—权益变动报告书》等相关法律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反其章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露了信息披露义务人在绿康生化中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通 过任何其他方式增加或减少其在绿康生化中拥有权益的股份。 四、本次权益变动是根据本报告书所载明的资料进 ...

上市公司：绿康生化股份有限公司 上市地点：深圳证券交易所 股票简称：绿康生化 股票代码：002868.SZ 信息披露义务人：杭州义睿投资合伙企业（有限合伙） 住所：浙江省杭州市富阳区东洲街道黄公望金融小镇黄公望路 3 幢 817 工位 通讯地址：浙江省杭州市富阳区东洲街道黄公望金融小镇黄公望路 3 幢 817 工位 股份权益变动性质：股份减少（协议转让） 签署日期：二〇二五年四月二十七日 信息披露义务人声明 1 一、本报告书系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号—权益变动报告书》等相关法律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反其章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露了信息披露义务人在绿康生化中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通 过任何其他方式增加或减少其在绿康生化中拥有权益的股份。 四、本次权益变动是根据本报告书 ...

上市公司：绿康生化股份有限公司 信息披露义务人：上海康怡投资有限公司 注册地：中国（上海）自由贸易试验区临港新片区新四平公路 468 弄 14 幢 17 号 一致行动人 1：赖潭平 住所：福建省浦城县 一致行动人 2：赖建平 住所：福建省浦城县 股份权益变动性质：股份减少（协议转让） 签署日期：2025 年 4 月 27 日 上市地点：深圳证券交易所 股票简称：绿康生化 股票代码：002868.SZ 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号—权益变动报告书》等相关法律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反其章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露了信息披露义务人在绿康生化中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通 过任何其他方式增加或减少其在绿康生化中拥有权益的股份。 四、本次权益变动是根据 ...

上市公司：绿康生化股份有限公司 股票代码：002868.SZ 信息披露义务人：杭州皓赢投资合伙企业（有限合伙） 住所：浙江省杭州市富阳区东洲街道黄公望金融小镇黄公望路 3 幢 251 工位 通讯地址：浙江省杭州市富阳区东洲街道黄公望金融小镇黄公望路 3 幢 251 工位 股份权益变动性质：股份减少（协议转让） 签署日期：二〇二五年四月二十七日 1 信息披露义务人声明 上市地点：深圳证券交易所 股票简称：绿康生化 | | | | | | 一、本报告书系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号—权益变动报告书》等相关法律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反其章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露了信息披露义务人在绿康生化中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通 过任何其他方式增加或减少其在绿康生化中拥有权益的股份。 四、本 ...